Microglial activation has been recognized as being vital in the pathogenesis of several neurodegenerative disorders. Therefore, the identification of therapeutic drugs to prevent microglial activation and thus protect against inflammationmediated neuronal injury, is required. In the present study, dextromethorphan (DM), a compound widely used in antitussive remedies that has been demonstrated to possess neuroprotective effects, was shown to reduce proinflammatory mediator production in lipopolysaccharide (LPS)stimulated BV2 mouse microglial cells. Western blot analysis revealed that DM markedly suppressed the activation of nuclear factorκB (NFκB), caspase3 signaling and the expression of another inflammationinducing factor, heat shock protein 60 (HSP60) and heat shock factor1, induced by LPS in BV2 cells. Results from ELISA assay demonstrated that DM reduced the release of HSP60, nitric oxide (NO), inducible NO synthase, tumor necrosis factorα, interleukin (IL)1β and IL6 induced by LPS in BV2 microglia. These results were confirmed by immunofluorescence, suggesting that DM may exert a neuroprotective and antiinflammatory effect by inhibiting microglial activation through the HSP60NFκB signaling pathway. Therefore, DM may offer substantial therapeutic benefits in the treatment of neurodegenerative diseases that are accompanied by microglial activation.
CITATION STYLE
Cheng, W., Li, Y., Hou, X., Bai, B., Li, F., Ding, F., … Wang, Y. (2015). Determining the neuroprotective effects of dextromethorphan in lipopolysaccharidestimulated BV2 microglia. Molecular Medicine Reports, 11(2), 1132–1138. https://doi.org/10.3892/mmr.2014.2794
Mendeley helps you to discover research relevant for your work.